Status:
RECRUITING
Glypican-3 as a Prognostic Factor in Patients With Hepatocellular Carcinoma Treated by Immunotherapy
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
Hepatocellular Carcinoma
Eligibility:
All Genders
18-90 years
Brief Summary
Recently, the positive results of the Imbrave 150 study (randomized study comparing Atezolizumab+Bevacizumab versus Sorafenib) prompted investigators to redefine their management strategy for advanced...
Detailed Description
When hepatocellular carcinoma (HCC) is diagnosed, only 25% of patients will be able to have a curative treatment such as liver transplantation, treatment by ablation or surgical resection. In the majo...
Eligibility Criteria
Inclusion
- 18 years ≤ age \< 90 years
- Diagnosed with HCC developed on a cirrhotic liver or on chronic liver disease that has not reached the stage of cirrhosis regardless of the etiology diagnosed according to the diagnostic criteria for TNCD updated in June 2021 (1)
- Having an indication for systemic therapy with Atezolizumab+Bevacizumab validated in multidisciplinary meeting according to the current recommendations of cancer societies.
- Understanding the French language.
- Having been informed and accepted to participate to the study.
Exclusion
- HIV or known immune deficiency or immunosuppressive treatment
- Autoimmune diseases or other immunotherapies
- History of portosystemic shunt or liver transplantation
- Sepsis, vasoconstrictor drugs.
- Pregnant or breastfeeding women
- Protected populations: under guardianship or curators
Key Trial Info
Start Date :
September 8 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 8 2029
Estimated Enrollment :
240 Patients enrolled
Trial Details
Trial ID
NCT05263830
Start Date
September 8 2023
End Date
September 8 2029
Last Update
December 16 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Service hépato-gastroentérologie, Hôpital la Pitié-Salpêtrière
Paris, France, 75013